Carsten Ohlmann

Dare to spare ADT in mCRPC? Are we ready for a SPAREtwo trial? #spare_ll_trial

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

CHMP recommends durvalumab for EU approval as the first perioperative immunotherapy for MIBC. @ASCO @myESMO @Uroweb @OncoAlert @OncBrothers @Uromigos @ProfSyedHussain @JimCatto astrazeneca.com/media-centre/p…

Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

Big news! The European Medicines Agency’s Committee for Medicinal Products for Human Use approved Belzutifan for advanced kidney cancer and VHL disease: actionkidneycancer.org/belzutifan-app… #KidneyCancer @ACTION4KC

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade @Cancer_Cell @OncoAlert @tompowles1 @PGrivasMDPhD

Positive PFS results for the AKT inhibitor capivasertib in hormone sensitive PTEN defficent prostate cancer (with Abi and ADT). A trend towards OS (immature) described. Chemotherapy triplets are also used in high volume disease. astrazeneca.com/media-centre/p…

Honored to present #AVENGER study results #EMUC24 - full story just submitted for publication @EUplatinum @AdvancesTherapy @Uroweb @UKSH_KI_HL @ch_ohlmann

Begehbare Riesenprostata am Universitätsspital Zürich #USZ vom 04.-05. November 2024. Erleben Sie die #Prostata im #Movember hautnah. usz.ch/veranstaltung/…

Prior #ARANOTE #ESMO24 data @scserendipity1 @grimm_mo @myESMO @OncoAlert @Uroweb @Silke_Gillessen @APCCC_Lugano @neerajaiims @DrYukselUrun @nataliagandur @cdanicas @DGUrologie @Uroweb @declangmurphy

🚨4-year follow-up of the Gothenburg MRI-targeted only vs systematic biopsy for 🚨 @NEJM >13k patients studied Biopsies of only MRI lesions leads to... 📉tiny.cc/otinzz

🚨 Morgen startet der Deutsche Urologenkongress in Leipzig! 🩺 Freut euch auf spannende Vorträge, neueste Forschungsergebnisse und den Austausch mit Kolleg:innen aus der Urologie. #DGU24 #Urologie #Leipzig @wulfingc @DGUrologie @dgukongress @GeSRU_de @GesruAcademics @BDUrologie

@tompowles1 @NEJM Great data, no doubt. Congratulations! Just two remarks: 1st not every T2 patient seems to benefit; 2nd what is the pCR rate in T2/3 in view of a bladder sparing approach?

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer. Published in @nejm gbr01.safelinks.protection.outlook.com/?url=https%3A%…

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Happy to share this team effort - first presented ⁦@ASCO 24⁩ by Wolfgang Fendler. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer ⁦@ProfKHerrmann⁩ ⁦@UniklinikEssen⁩ sciencedirect.com/science/articl…

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

Change in Total Lesion PSMA (TLP) predicts survival in pts with mCRPC treated with Lu-PSMA therapy lnkd.in/d8aCa4MH @Prof_Ezziddin

Great to have @tompowles1 at #UroTrials in Düsseldorf. Prediction: 80% less cystectomies in the next five years given recent advances in the field. So rCx only in case of local complications/bleeding in the future? @amerseburger @JimCatto @daviesbj @uretericbud

Great 1. Day #urotrials meeting - kudos to @grimm_mo for setting this up 👋 @OncoAlert @APCCC_Lugano @tompowles1